The use of intravenous immunoglobulin in Miller Fisher syndrome.
We report a patient with Miller Fisher syndrome who was treated with an intravenous high-dose of immunoglobulin. This syndrome is considered to be a benign variety of acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). However, there have been several reports of the need for ventilatory support and a few cases have had a fatal outcome. We observed a case of progressive Miller Fisher syndrome in a 3-year-old boy. Following 2 episodes of apnea lasting about 50 s each, he was treated with intravenous immunoglobulin (400 mg/kg/day) for 5 consecutive days. His respiratory state, general muscle strength, truncal ataxia and emotional state improved remarkably after this therapy.
Arakawa
Y
Y
Department of Pediatrics, Jichi Medical School, Tochigi-Ken, Japan.
Yoshimura
M
M
Kobayashi
S
S
Ichihashi
K
K
Miyao
M
M
Momoi
M Y
MY
Yanagisawa
M
M
D001259:Ataxia / Q000628:therapy*; D002675:Child, Preschool; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use*; D008297:Male; D009886:Ophthalmoplegia / Q000628:therapy*; D011129:Polyradiculoneuropathy / Q000628:therapy*; D012018:Reflex; D013577:Syndrome
D016756:Immunoglobulins, Intravenous